CCL2 and breast cancer: Compared to mammary tumor-bearing mice receiving Ca-TAT/control siRNA (4T1.Ctrl), Ca-TAT/CCL2 siRNA (4T1.CCL2si) treatment enhanced lean mass and did not affect grip strength, fat mass or overall body mass (Fig. 6B-E; unnormalized data shown in Fig. S11A-C).